Company Releases
Accent Therapeutics | May 22, 2025
Accent Therapeutics Presents Data Supporting Therapeutic Potential of First-in-Class DHX9 Inhibitor, ATX-559, and Novel KIF18A Inhibitor, ATX-295, at the AACR Annual Meeting 2025
Accent Therapeutics | April 28, 2025
Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of Novel KIF18A Inhibitor ATX-295 and Receives FDA Fast Track Designation for Lead Assets ATX-295 and DHX9 Inhibitor ATX-559
Accent Therapeutics | April 15, 2025
Attovia Therapeutics Announces $90 Million Series C Financing to Advance ATTOBODY-based Programs through Clinical Proof of Concept
GlobeNewswire | April 15, 2025
Accent Therapeutics to Present Data on Lead Programs ATX-559 and ATX-295 at the 2025 American Association for Cancer Research Annual Meeting
Accent Therapeutics | March 25, 2025
Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager
Candid Therapeutics | January 6, 2025
Candid Therapeutics and EpimAb Biotherapeutics Enter Into Research Collaboration to Discover and Develop Novel T-Cell Engagers for Autoimmune Indications
Candid Therapeutics | December 16, 2024
Candid Therapeutics and Ab Studio Enter Into Research Collaboration to Discover and Develop Novel T Cell Engagers for Autoimmune Indications
Candid Therapeutics | December 16, 2024
Nona Biosciences Announces Discovery Collaboration with Candid Therapeutics for Next-Generation T-Cell Engagers
Candid Therapeutics | December 16, 2024
Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of ATX-559 and Chief Scientific Officer Transition
Accent Therapeutics | December 11, 2024
Accent Therapeutics Announces FDA Clearance of IND Application for ATX-559, a First-In-Class Oral DHX9 Inhibitor
Accent Therapeutics | October 24, 2024
With $370M debut, Candid Therapeutics is upfront about goal to lead a coming T-cell engager wave
Fierce Biotech | September 10, 2024
Candid Therapeutics Debuts with $370M Capital Raise to Clinically Evaluate Potentially Transformative Autoimmune Therapies
Business Wire | September 9, 2024
RayzeBio, Dice alums raise $370 million for new autoimmune startup
STAT | September 9, 2024
Investors pour $370M+ into Ken Song's autoimmune biotech after his RayzeBio success
Endpoints News | September 9, 2024
Little-known startup, backed by Foresite and Samsara, swings $60M China I&I deal
Endpoints News | September 4, 2024
EpimAb Biotherapeutics and Vignette Bio Announce Strategic Collaboration to Develop EMB-06, a BCMA×CD3 Bispecific Antibody
GlobeNewswire | September 3, 2024
Two more pharmas practice their Accent, invest in $75M series C round
Fierce Biotech | January 23, 2024
Oncology biotech Accent raises $75M to enter the clinic
Endpoints News | January 23, 2024
Pharmas back Accent’s plan to make RNA-targeting cancer drugs
Biopharma Dive | January 23, 2024
Bristol Myers, J&J fund Lexington cancer biotech’s move into the clinic
Boston Business Journal | January 23, 2024
Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies
PR Newswire | January 23, 2024